Ipsen, Université de Montréal and IRICoR Expands their Collaboration for Pre-Clinical Stage Program and two New Discovery-Stage Programs
Shots:
- Ipsen exercised its option to acquire exclusive rights to a pre-clinical stage program in oncology & will now lead all development & commercialization activities of the licensed asset, under May 2020 license agreement. Université de Montréal receives an up front, development & commercial milestones along with royalties
- Ipsen, Université de Montréal & IRICoR will continue their partnership with a new collaboration & option to license 2 new oncology discovery-stage programs
- Université de Montréal will receive up front & research funding for 2 compounds & additional fees upon achievement of development & commercial milestones along with royalties while Ipsen will lead the development activities & commercialization of drug candidates globally if exercise its option
Ref: Ipsen | Image: Ipsen
Related News:- Ipsen Receives CHMP Negative Opinion for Palovarotene to Treat Fibrodysplasia Ossificans Progressiva
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
